Skip to Main Content

Paper Details

A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma.
J Clin Endocrinol Metab
8
2021
ATC, Anaplastic Thyroid Carcinoma, BRAF, BRAF-mutated ATC, LBH-589, MEK, PDX, PDX models, anaplastic thyroid carcinoma, cancer, cancer cell lines, cancers, docetaxel, human, mutant TP53, papillary thyroid carcinoma, patient, patients, pralatrexate, thyroid cancers, tumor
Author NameAffiliation
Michelle D WilliamsThe University of Texas MD Anderson Cancer Center
Steven E SchererBaylor College of Medicine
Steven E SchererBaylor College of Medicine
David A WheelerBaylor College of Medicine
David A WheelerSt. Jude Children's Research Hospital
David A WheelerBaylor College of Medicine
David A WheelerSt. Jude Children's Research Hospital
Stephen Y LaiThe University of Texas MD Anderson Cancer Center
Stephen Y LaiThe University of Texas MD Anderson Cancer Center
Stephen Y LaiThe University of Texas MD Anderson Cancer Center
  • 1 - 10

Datasets

Release 1.2